Is this your business? Claim it to manage your IP and profile
The xT CDx is an FDA-approved tumor profiling platform designed for solid tumor malignancies. This cutting-edge system employs a 648-gene panel to conduct DNA sequencing of solid tumors, matched to normal tissue samples such as blood or saliva. It provides detailed insight into single nucleotide variations, multi-nucleotide variants, insertions, deletions, and microsatellite instability statuses. In addition to aiding in identifying therapy candidates, it offers comprehensive tumor mutation profiling in alignment with professional oncology guidelines. A single-site assay executed at Tempus Labs, xT CDx is pivotal for ensuring personalized cancer treatment by aligning genomic data with therapeutic selections.
The xF+ Liquid Biopsy Panel is designed to extend the diagnostic capabilities for detecting cancer-related genomic alterations in circulating tumor DNA (ctDNA). Featuring a comprehensive sequencing panel with up to 523 genes, it focuses on identifying mutations not detectable through conventional solid tumor analysis alone. This test provides a unique opportunity to maximize the detection of biomarker presence for targeted therapies, thus addressing a critical area of precision oncology. The addition of liquid biopsy testing enhances early detection, monitoring of disease progression, and evaluation of treatment responses in real-time, for a holistic view of tumor biology.
The DPYD Test by Tempus is an advanced assay designed to identify genetic variants in the dihydropyrimidine dehydrogenase gene, which plays a critical role in metabolizing chemotherapy drugs like 5-FU and capecitabine. This test is vital for assessing patient risk for severe toxicity and adverse reactions to these medications, ensuring safer treatment plans. By targeting key genetic points, the DPYD Test offers clinicians critical insights into individual patient susceptibility, marking a significant advancement in personalized chemotherapy regimens.
Tempus xT CDx represents a sophisticated approach to genomic profiling aimed at solid tumor malignancies, classified through DNA sequencing from both tumor and matched normal samples. This 648-gene panel spans a broad spectrum of genetic alterations, including INDELs and MSIs, and is strategically positioned to guide treatment protocols through detailed molecular diagnostics. As an essential instrument in personalized medicine, Tempus xT CDx not only supports targeted therapy identification but also enhances the selection process for applicable clinical trials by providing profound insights into a tumor's genetic landscape.
Intel expands its foundry ecosystem with alliances with TSMC, UMC, and Taiwanese tech partners, marking a major transformation for the firm's production strategy. Read more
Join the world's most advanced semiconductor IP marketplace!
It's free, and you'll get all the tools you need to discover IP, meet vendors and manage your IP workflow!
No credit card or payment details required.
Join the world's most advanced AI-powered semiconductor IP marketplace!
It's free, and you'll get all the tools you need to advertise and discover semiconductor IP, keep up-to-date with the latest semiconductor news and more!
Plus we'll send you our free weekly report on the semiconductor industry and the latest IP launches!
To evaluate IP you need to be logged into a buyer profile. Select a profile below, or create a new buyer profile for your company.
